Addison Advisors LLC Sells 213 Shares of Becton, Dickinson and Company (NYSE:BDX)

Addison Advisors LLC reduced its position in Becton, Dickinson and Company (NYSE:BDX) by 30.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 480 shares of the medical instruments supplier’s stock after selling 213 shares during the quarter. Addison Advisors LLC’s holdings in Becton, Dickinson and Company were worth $109,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Bank of Jackson Hole Trust purchased a new stake in Becton, Dickinson and Company in the 4th quarter worth approximately $25,000. Sierra Ocean LLC bought a new position in shares of Becton, Dickinson and Company in the fourth quarter worth $29,000. Ashton Thomas Securities LLC purchased a new stake in shares of Becton, Dickinson and Company in the third quarter worth $33,000. Tompkins Financial Corp boosted its stake in Becton, Dickinson and Company by 44.2% during the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 46 shares during the period. Finally, Kennebec Savings Bank purchased a new position in Becton, Dickinson and Company during the third quarter worth about $46,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on BDX. StockNews.com downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Tuesday. Barclays lifted their target price on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Finally, Piper Sandler increased their price target on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, January 28th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $278.29.

Becton, Dickinson and Company Stock Down 0.1 %

Shares of NYSE BDX opened at $230.14 on Wednesday. The stock has a market capitalization of $66.08 billion, a P/E ratio of 38.23, a PEG ratio of 1.63 and a beta of 0.40. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $251.99. The firm’s 50 day simple moving average is $233.05 and its two-hundred day simple moving average is $233.21. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. As a group, analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be issued a $1.04 dividend. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 annualized dividend and a dividend yield of 1.81%. Becton, Dickinson and Company’s dividend payout ratio is currently 69.10%.

Becton, Dickinson and Company declared that its board has initiated a share repurchase plan on Tuesday, January 28th that permits the company to repurchase 10,000,000 outstanding shares. This repurchase authorization permits the medical instruments supplier to buy shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

Insider Activity

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 700 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $227.99, for a total value of $159,593.00. Following the transaction, the director now directly owns 36,033 shares of the company’s stock, valued at $8,215,163.67. The trade was a 1.91 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Roland Goette sold 4,483 shares of the stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $221.01, for a total value of $990,787.83. Following the sale, the executive vice president now directly owns 24,345 shares of the company’s stock, valued at approximately $5,380,488.45. This trade represents a 15.55 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 10,544 shares of company stock valued at $2,370,309. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.